Epirubicin plus cyclophosphamide followed by docetaxel plus trastuzumab and bevacizumab as neoadjuvant therapy for HER2-positive locally advanced breast cancer (LABC) or as adjuvant therapy for HER2-positive pathologic stage III breast cancer (PS3BC): A phase II trial of the NSABP Foundation Research Group

被引：0
|
作者：
Smith, J. W. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Buyse, M. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Rastogi, P. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Geyer, C., Jr. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Jacobs, S. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Patocskai, E. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
Wolmark, N. [1 ,2 ,3 ,4 ,5 ,6 ,7 ]
机构：
[1] Columbia River Oncol Program, Portland, OR USA
[2] IDDI, Louvain, Belgium
[3] NSABP, Pittsburgh, PA USA
[4] UPCI, Magee Womens Hosp, Womens Canc Clin, Pittsburgh, PA USA
[5] Allegheny Gen Hosp, Pittsburgh, PA 15212 USA
[6] Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA
[7] Univ Montreal, Ctr Hosp, Montreal, PQ, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
580
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II Southwest Oncology Group study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer
    Kash, J.
    Barlow, W. E.
    Albain, K. S.
    Gralow, J. R.
    Lew, D.
    Flaherty, L. E.
    Royce, M. E.
    Hortobagyi, G. N.
    Livingston, R. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] Effect of TOP2A and cMYC gene copy number on outcome in a Phase II trial of adjuvant TC (Docetaxel/Cyclophosphamide) plus trastuzumab (HER TC) in HER2-positive early stage breast cancer
    Jones, S.
    Collea, R.
    Paul, D.
    Sedlacek, S.
    Favret, A.
    Gore, I.
    Lindquist, D. L.
    Holmes, F. A.
    Allison, M. A. K.
    Steinberg, M. S.
    Stokoe, C.
    Portillo, R. M.
    Crockett, M.
    Wang, Y.
    Lina, A.
    Robert, N. J.
    O'Shaughnessy, J.
    CANCER RESEARCH, 2012, 72
  • [43] Pertuzumab in Combination with Trastuzumab and Docetaxel as Adjuvant Doublet Therapy for HER2-Positive Breast Cancer: A Systematic Review
    Ventura, Ignacio
    Salcedo, Nerea Pinilla
    Perez-Bermejo, Marcelino
    Perez-Murillo, Javier
    Tejeda-Adell, Manuel
    Tomas-Aguirre, Francisco
    Legidos-Garcia, Maria Ester
    Murillo-Llorente, Maria Teresa
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2025, 26 (05)
  • [44] Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial
    Zhou, Hao
    Wang, Lei
    Wang, Lei
    Guo, Zhaoji
    CANCER RESEARCH, 2023, 83 (05)
  • [45] Ribociclib Plus Trastuzumab in Advanced HER2-Positive Breast Cancer: Results of a Phase 1b/2 Trial
    Goel, Shom
    Pernas, Sonia
    Tan-Wasielewski, Zhenying
    Barry, William T.
    Bardia, Aditya
    Rees, Rebecca
    Andrews, Chelsea
    Tahara, Rie Kawabori
    Trippa, Lorenzo
    Mayer, Erica L.
    Winer, Eric P.
    Spring, Laura M.
    Tolaney, Sara M.
    CLINICAL BREAST CANCER, 2019, 19 (06) : 399 - 404
  • [46] Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer
    Loesch, David
    Asmar, Lina
    McIntyre, Kristi
    Doane, Lisa
    Monticelli, Michael
    Paul, Devchand
    Vukelja, Svetislava
    Orlando, Mauro
    Vaughn, LaTrice G.
    Zhan, Feng
    Boehm, Kristi A.
    O'Shaughnessy, Joyce A.
    CLINICAL BREAST CANCER, 2008, 8 (02) : 178 - 186
  • [47] Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China: The Nvwa study
    Li, Junjie
    Shao, Zhimin
    Xu, Binghe
    Jiang, Zefei
    Cui, Shude
    Zhang, Jin
    Liao, Ning
    Jiang, Jun
    Wang, Yongsheng
    Ouyang, Quchang
    Ying, Ziwei
    MEDICINE, 2018, 97 (21)
  • [48] Neoadjuvant pyrotinib plus trastuzumab, docetaxel, and carboplatin in patients with HER2-positive early breast cancer: A single-group, multicenter, phase II study
    Liu, Z.
    Zhu, J.
    Wang, C.
    Sun, X.
    Lu, Z.
    Chen, X.
    Wang, H.
    Mao, S.
    Zhou, Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S331 - S331
  • [49] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [50] Adjuvant Trastuzumab for 6 Months is Effective in Patients with HER2-positive Stage II or III Breast Cancer
    Tai, Cheng-Jeng
    Pan, Chin-Kwun
    Chen, Ching-Shyang
    Hung, Chin-Sheng
    Wu, Chih-Hsiung
    Chiou, Hung-Yi
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2013, 14 (03) : 1981 - 1984
12345